Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Adocia has started a double-blinded Phase IIa study to compare variabilities of HinsBet and NovoLog with three repeated injections of each product to each patient.
Subscribe to our email newsletter
The company will evaluate around 20 patients with type 1 diabetes in the Phase IIa trial.
The results from a Phase I trial demonstrated that the action of HinsBet is as fast as that of NovoLog and has less variability.
Adocia president and CEO Gerard Soula said they expect the study to confirm HinsBet’s similar efficacy on type 1 diabetics compared with Novo Nordisk’s fast-acting insulin analog.